Identification

Name
GENTAMICIN C1A
Accession Number
DB04729
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Gentamicin c1a sulfateS7K05PO15737713-04-5HNCAOLPMSASREN-UCMBPTNBSA-N
Categories
UNII
AV4A72IATD
CAS number
Not Available
Weight
Average: 449.5423
Monoisotopic: 449.284948627
Chemical Formula
C19H39N5O7
InChI Key
VEGXETMJINRLTH-BOZYPMBZSA-N
InChI
InChI=1S/C19H39N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h8-18,24-27H,3-7,20-23H2,1-2H3/t8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-/m0/s1
IUPAC Name
(2R,3R,4R,5R)-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
A30S ribosomal protein S12
adduct
Escherichia coli (strain K12)
A16S rRNA
adduct
Enteric bacteria and other eubacteria
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
AcemetacinAcemetacin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with GENTAMICIN C1A.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with GENTAMICIN C1A.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Withdrawn
AlcuroniumGENTAMICIN C1A may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidGENTAMICIN C1A may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of GENTAMICIN C1A.Approved, Investigational
AmpicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumGENTAMICIN C1A may increase the respiratory depressant activities of Atracurium.Experimental
Atracurium besylateGENTAMICIN C1A may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
AzidocillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
BendazacBendazac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Botulinum Toxin Type AGENTAMICIN C1A may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BGENTAMICIN C1A may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with GENTAMICIN C1A.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of GENTAMICIN C1A.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
CarbenicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Carbenicillin.Approved
Carbenicillin indanylThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Carbenicillin indanyl.Approved
CarboplatinGENTAMICIN C1A may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
CisatracuriumGENTAMICIN C1A may increase the respiratory depressant activities of Cisatracurium.Experimental
Cisatracurium besylateGENTAMICIN C1A may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of GENTAMICIN C1A.Approved
Clodronic AcidGENTAMICIN C1A may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
CloxacillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateGENTAMICIN C1A may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Cyclacillin.Approved
CyclosporineGENTAMICIN C1A may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with GENTAMICIN C1A.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
DecamethoniumGENTAMICIN C1A may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with GENTAMICIN C1A.Approved
DiclofenacDiclofenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with GENTAMICIN C1A.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with GENTAMICIN C1A.Approved
Domoic AcidGENTAMICIN C1A may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideGENTAMICIN C1A may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
EpicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with GENTAMICIN C1A.Approved
EtanerceptEtanercept may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Etidronic acidGENTAMICIN C1A may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of GENTAMICIN C1A.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with GENTAMICIN C1A.Approved, Vet Approved
GallamineGENTAMICIN C1A may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideGENTAMICIN C1A may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with GENTAMICIN C1A.Experimental
GuacetisalGuacetisal may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
IbandronateGENTAMICIN C1A may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with GENTAMICIN C1A.Experimental
LeflunomideLeflunomide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of GENTAMICIN C1A.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
MecamylamineGENTAMICIN C1A may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Withdrawn
MetampicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Meticillin.Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with GENTAMICIN C1A.Experimental
MetocurineGENTAMICIN C1A may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideGENTAMICIN C1A may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Mezlocillin.Approved
MivacuriumGENTAMICIN C1A may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinGENTAMICIN C1A may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with GENTAMICIN C1A.Experimental
OlopatadineOlopatadine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with GENTAMICIN C1A.Approved
OxacillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Withdrawn
PamidronateGENTAMICIN C1A may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumGENTAMICIN C1A may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with GENTAMICIN C1A.Experimental
PhenoxymethylpenicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
PipecuroniumGENTAMICIN C1A may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with GENTAMICIN C1A.Experimental
PirfenidonePirfenidone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Procaine benzylpenicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
PropicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with GENTAMICIN C1A.Experimental
PTC299PTC299 may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
PyrantelGENTAMICIN C1A may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumGENTAMICIN C1A may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental, Investigational
RisedronateGENTAMICIN C1A may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumGENTAMICIN C1A may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
SuccinylcholineGENTAMICIN C1A may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
SultamicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
TazobactamThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateGENTAMICIN C1A may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateGENTAMICIN C1A may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of GENTAMICIN C1A can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
TicarcillinThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
Tiludronic acidGENTAMICIN C1A may increase the hypocalcemic activities of Tiludronic acid.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with GENTAMICIN C1A.Approved
TranilastTranilast may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational
TubocurarineGENTAMICIN C1A may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of GENTAMICIN C1A.Approved
VecuroniumGENTAMICIN C1A may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidGENTAMICIN C1A may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
KEGG Compound
C00908
PubChem Compound
72396
PubChem Substance
46505724
ChemSpider
65329
ChEBI
27784
ChEMBL
CHEMBL194126
HET
LLL
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
2et3 / 3ham / 4lf4 / 4lf9 / 4v53 / 4v55
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility20.5 mg/mLALOGPS
logP-2.2ALOGPS
logP-4ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)10ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area213.72 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity108.83 m3·mol-1ChemAxon
Polarizability47.46 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9691
Blood Brain Barrier-0.9812
Caco-2 permeable-0.7232
P-glycoprotein substrateSubstrate0.7767
P-glycoprotein inhibitor INon-inhibitor0.659
P-glycoprotein inhibitor IINon-inhibitor0.873
Renal organic cation transporterNon-inhibitor0.8371
CYP450 2C9 substrateNon-substrate0.8321
CYP450 2D6 substrateNon-substrate0.7952
CYP450 3A4 substrateSubstrate0.5286
CYP450 1A2 substrateNon-inhibitor0.9169
CYP450 2C9 inhibitorNon-inhibitor0.9187
CYP450 2D6 inhibitorNon-inhibitor0.9049
CYP450 2C19 inhibitorNon-inhibitor0.8876
CYP450 3A4 inhibitorNon-inhibitor0.9756
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9421
Ames testNon AMES toxic0.7877
CarcinogenicityNon-carcinogens0.96
BiodegradationNot ready biodegradable0.9876
Rat acute toxicity1.8005 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.978
hERG inhibition (predictor II)Non-inhibitor0.6741
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminocyclitol glycosides
Alternative Parents
2-deoxystreptamine aminoglycosides / O-glycosyl compounds / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Monosaccharides / Tertiary alcohols / 1,2-aminoalcohols / Oxacyclic compounds
show 5 more
Substituents
Amino cyclitol glycoside / 2-deoxystreptamine aminoglycoside / Glycosyl compound / O-glycosyl compound / Aminocyclitol or derivatives / Cyclohexanol / Cyclohexylamine / Cyclitol or derivatives / Monosaccharide / Oxane
show 18 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
gentamycin C (CHEBI:27784)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Adduct
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
rpsL
Uniprot ID
P0A7S3
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Gill AE, Amyes SG: The contribution of a novel ribosomal S12 mutation to aminoglycoside resistance of Escherichia coli mutants. J Chemother. 2004 Aug;16(4):347-9. [PubMed:15332709]
  4. Tamehiro N, Hosaka T, Xu J, Hu H, Otake N, Ochi K: Innovative approach for improvement of an antibiotic-overproducing industrial strain of Streptomyces albus. Appl Environ Microbiol. 2003 Nov;69(11):6412-7. [PubMed:14602594]
  5. Hu H, Ochi K: Novel approach for improving the productivity of antibiotic-producing strains by inducing combined resistant mutations. Appl Environ Microbiol. 2001 Apr;67(4):1885-92. [PubMed:11282646]
  6. Schroeder R, Waldsich C, Wank H: Modulation of RNA function by aminoglycoside antibiotics. EMBO J. 2000 Jan 4;19(1):1-9. [PubMed:10619838]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Adduct
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Doi Y, de Oliveira Garcia D, Adams J, Paterson DL: Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother. 2007 Mar;51(3):852-6. Epub 2006 Dec 11. [PubMed:17158944]
  4. Bogaerts P, Galimand M, Bauraing C, Deplano A, Vanhoof R, De Mendonca R, Rodriguez-Villalobos H, Struelens M, Glupczynski Y: Emergence of ArmA and RmtB aminoglycoside resistance 16S rRNA methylases in Belgium. J Antimicrob Chemother. 2007 Mar;59(3):459-64. Epub 2007 Jan 15. [PubMed:17224412]
  5. Aslangul E, Massias L, Meulemans A, Chau F, Andremont A, Courvalin P, Fantin B, Ruimy R: Acquired gentamicin resistance by permeability impairment in Enterococcus faecalis. Antimicrob Agents Chemother. 2006 Nov;50(11):3615-21. [PubMed:17065620]
  6. Schroeder R, Waldsich C, Wank H: Modulation of RNA function by aminoglycoside antibiotics. EMBO J. 2000 Jan 4;19(1):1-9. [PubMed:10619838]

Drug created on September 11, 2007 11:49 / Updated on October 02, 2017 05:37